protein

Human Interferon-gamma, Recombinant

MBS319052

0.02 mg

165 USD

Recombinant Protein

Human Interferon-gamma, Recombinant

Interferon gamma (IFN-gamma) Recombinant

interferon-gamma; Interferon gamma; interferon gamma; IFN-gamma; immune interferon; OTTHUMP00000240111; interferon, gamma; Immune interferon

IFNG; IFNG; IFG; IFI

IFNG_HUMAN

E Coli

Human

166

Met-Gln-Asp-Pro-Tyr.

Interferon gamma (IFN-gamma) Recombinant

>98% (SDS-PAGE and RP-HPLC analysis). Purified by chromatographic techniques. Product is sterile filtered.

Purified, Lyophilized. Reconstitute using sterile deionized water to a concentration of >=100ug/ml. Further dilutions can be made in other aqueous buffers.

1mg/ml (prior to lyophilization) (OD280nm, E^0.1% = 0.64)

The lyophilized product, though stable for 3 weeks at room temperature, is best stored at -20 degree C. After reconstitution, short term (up to 1 week) store at 2 to 8 degree C. Long-term, add 0.1% HSA or BSA, aliquot and store at -20 degree C.

Specific activity as determined in a viral resistance assay is <=0.05ng/ml, corresponding to a specific activity of 2 x 10^7 IU/mg. Each laboratory should determine an optimum working titer for use in its particular application. Other applications have not been tested but use in such assays should not necessarily be excluded.

Inactivation: Not applicable

Buffer: Lyophilized from 10mM Sodium phosphate buffer, pH 7.4 +/- 0.1. Preservative: No. Lyophilized: Yes

Purified Cytokines and Growth Factors

Recombinant Human Interferon-gamma. Recombinant Human Interferon-gamma is a single, non-glycosylated, polypeptide chain containing 144 amino acids and having a molecular mass of 16,879 Dalton. The sequence of the first five N-terminal amino acids was de

184639

AAB59534.1

P01579

ATF-2 Transcription Factor Network Pathway (138006); African Trypanosomiasis Pathway (194384); African Trypanosomiasis Pathway (194323); Allograft Rejection Pathway (83123); Allograft Rejection Pathway (535); Amoebiasis Pathway (167324); Amoebiasis Pathway (167191); Antigen Processing And Presentation Pathway (83074); Antigen Processing And Presentation Pathway (485); Calcineurin-regulated NFAT-dependent Transcription In Lymphocytes Pathway (137993)

This gene encodes a member of the type II interferon family. The protein encoded is a soluble cytokine with antiviral, immunoregulatory and anti-tumor properties and is a potent activator of macrophages. Mutations in this gene are associated with aplastic anemia.

Function: Produced by lymphocytes activated by specific antigens or mitogens. IFN-gamma, in addition to having antiviral activity, has important immunoregulatory functions. It is a potent activator of macrophages, it has antiproliferative effects on transformed cells and it can potentiate the antiviral and antitumor effects of the type I interferons. Subunit structure: Homodimer. Subcellular location: Secreted. Tissue specificity: Released primarily from activated T lymphocytes. Post-translational modification: Proteolytic processing produces C-terminal heterogeneity, with proteins ending alternatively at Gly-150, Met-157 or Gly-161. Involvement in disease: In Caucasians, genetic variation in IFNG is associated with the risk of aplastic anemia (AA) [. MIM:609135]. AA is a rare disease in which the reduction of the circulating blood cells results from damage to the stem cell pool in bone marrow. In most patients, the stem cell lesion is caused by an autoimmune attack. T-lymphocytes, activated by an endogenous or exogenous, and most often unknown antigenic stimulus, secrete cytokines, including IFN-gamma, which would in turn be able to suppress hematopoiesis. Pharmaceutical use: Available under the name Actimmune (Genentech). Used for reducing the frequency and severity of serious infections associated with chronic granulomatous disease (CGD). Sequence similarities: Belongs to the type II (or gamma) interferon family.

0.02 mg

165 USD